



Questionnaire on immunotherapy and risk perception for the study "Communication, Coordination and Security for people with Multiple Sclerosis (COCOS-MS)"

## Clinical Global Impression - Change of state

,						
1. Compared to the situation three months ago (for follow-up assessments: to the last data collection three months ago) how would you describe your general health situation (e.g., physical impairment, symptoms, emotional experience)?						
□ much better □ better □ somewhat besser □ unchanged □ somewhat worse □ worse □ much worse □ no statement possible						
Questions about your personal treatment decision on your current MS medication	on					
2. Are you currently being treated with any of the following medications? If so, since when?						
□ Natalizumab (Tysabri®) since:   □ Fingolimod (Gilenya®) since:   □ Siponimod (Mayzent®) since:   □ Ozanimod (Zeposia®) since:   □ Alemtzumab (Lemtrada®) since:   □ Ocrelizumab (Ocrevus®) since:   □ Rituximab (MabThera®) since:   □ Ofatumumab (Arzerra®) since:   □ Cladribine (Mavenclad®) since:   □ another, please specify: none; please specify reason, if applicable:						
3. How well informed do you feel about the medication?						
□ very good □ good □ rather good □ rather poor □ poor □ very poor □ no statement possible						
4. Which aspects were important for the selection of the current medication (multiple answers possible)? (answer only if you are currently being treated with one of the MS medications mentioned above)						
<ul> <li>□ Other medications did not help.</li> <li>□ The current medication is the most effective.</li> <li>□ I was in a hopeless situation.</li> <li>□ There were no alternatives.</li> <li>□ I was willing to take the risk.</li> <li>□ I'm not afraid of complications.</li> </ul> Immunotherapy and risk perception V01 0	1/3					
ssssss.	. , 0					

☐ The s ☐ It was ☐ other,	my do	ctor's de	cision.								
Autonomy preferences											
5. When you are faced with a decision about a MEDICAL TREATMENT IN GENERAL (examination or treatment), who should decide?											
<ul> <li>☐ I would like to make the decision by myself.</li> <li>☐ I would like to make the final decision by myself but consult with the doctor.</li> <li>☐ I would like to make the decision together with the doctor.</li> <li>☐ The doctor should make the final decision but consult with me.</li> <li>☐ The doctor should make the decision by himself.</li> </ul>											
6. If you	have to	o decide	whethe	r to conti	nue or d	liscontini	ue takin	g medica	itions, wh	no shoul	d decide?
<ul> <li>□ I would like to make the decision by myself.</li> <li>□ I would like to make the final decision by myself but consult with the doctor.</li> <li>□ I would like to make the decision together with the doctor.</li> <li>□ The doctor should make the final decision but consult with me.</li> <li>□ The doctor should make the decision by himself.</li> </ul>											
	Autonomy preferences on risk perception (please mark on the lines below) (cf.Boeije & Janssens 2004, Heesen et al., 2010)										
7.How s  Not severe a	1	do you th	iink youi	MS dise	ease is?	(cf. Hee	sen et a	nl., 2010) I 7	8	9	Extremely severe
8. How serious do you think your MS disease is? (cf. Boeije & Janssens 2004)											
Not serious		l		l		1		Ĺ			Extremely serious
at all	0	1	2	3	4	5	6	7	8	9	10
9. What	would	a wheeld	hair dep	pendency	y mean t	o you? (	cf. Boei	je & Jans	ssens 20	04)	
Not bad at all		ı		ĺ		ĺ	ĺ	ı		l	The worst thing I can 10 imagine
at an	0	1	2	3	4	5	6	7	8	9	10 imagine
Questions on risk perception (cf. Heesen et al., 2010)											
<u> </u>											
10. How would you assess the risk that your current MS therapy will result in a severe complication?											
Not high at all	0	1	2	3	4	5	6	7	8	9	Extremely high
Immunotl	nerapy a	and risk p	erceptior	n_V01_0							2/3

11. Given your medical history of MS and taking into account how you deal with risks in general: do you consider your PERSONAL risk of a severe complication to be lower or higher compared to other patients in the same situation?



12. How do you assess the risk of developing a severe infection?




12a. How do you assess the risk of developing a corona infection with a severe course?



**12b**. How do you assess the risk of developing a severe viral infection of the brain called progressive multifocal leukoencephalopathy (PML)?



**13**. Given your medical history of MS and taking into account how you deal with risks in general: do you consider your PERSONAL risk of a PML to be lower or higher compared to other patients in the same situation?



14. How would you estimate the benefits of your current MS therapy?

very	

□ high

☐ rather high

☐ rather low

 $\square$  low


□ very low

☐ no statement possible

15. At what risk of complications would you continue the therapy nevertheless?



16. At what risk of complications would you discontinue the therapy?



Immunotherapy and risk perception V01 0